Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN versus IPRIVASK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN versus IPRIVASK.
ARGATROBAN vs IPRIVASK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, XIII, and platelet aggregation.
Direct thrombin inhibitor; binds reversibly to the active site of free and clot-bound thrombin, inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Initial dose: 2 mcg/kg/min IV continuous infusion; adjust to maintain aPTT 1.5-3 times baseline. For patients with HIT undergoing PCI: initial bolus 350 mcg/kg IV, then 25 mcg/kg/min IV infusion.
Adults: 1 mg/kg intravenously twice daily.
None Documented
None Documented
Terminal half-life 39-51 minutes (dose-dependent); clinical context: continuous IV infusion required for stable anticoagulation.
Clinical Note
moderateArgatroban + Benzydamine
"Argatroban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateArgatroban + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Argatroban."
Clinical Note
moderateArgatroban + Droxicam
"Argatroban may increase the anticoagulant activities of Droxicam."
Clinical Note
moderateArgatroban + Loxoprofen
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment; up to 6 hours in severe impairment).
Primarily hepatic (CYP450) metabolism; fecal (~65% as unchanged and metabolites) and renal (~22% with ~16% unchanged) elimination.
Renal: 70% as unchanged drug; biliary/fecal: 30% (metabolites and unchanged drug).
Category C
Category C
Direct Thrombin Inhibitor
Direct Thrombin Inhibitor
"Argatroban may increase the anticoagulant activities of Loxoprofen."